Boston Scientific (NYSE:BSX) Price Target Raised to $128.00

Boston Scientific (NYSE:BSX) had its target price raised by Robert W. Baird from $123.00 to $128.00 in a research report sent to investors on Wednesday morning, MarketBeat Ratings reports. Robert W. Baird currently has an outperform rating on the medical equipment provider’s stock.

A number of other analysts have also recently commented on the stock. BTIG Research upped their price objective on shares of Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $118.00 to $125.00 in a report on Monday, September 8th. Raymond James Financial boosted their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 24th. Finally, Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $120.79.

Boston Scientific Stock Performance

Shares of BSX stock opened at $97.30 on Wednesday. The stock has a market cap of $144.17 billion, a PE ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61. The stock has a 50-day moving average of $102.93 and a 200-day moving average of $102.05. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific has a one year low of $80.64 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the firm earned $0.62 EPS. Boston Scientific’s quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts expect that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director directly owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $18,659,923.46. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 over the last quarter. Insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

Hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC grew its stake in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. Amplius Wealth Advisors LLC boosted its holdings in shares of Boston Scientific by 5.5% in the 1st quarter. Amplius Wealth Advisors LLC now owns 2,381 shares of the medical equipment provider’s stock valued at $240,000 after buying an additional 124 shares during the last quarter. Veracity Capital LLC bought a new position in shares of Boston Scientific in the first quarter valued at $210,000. Leverty Financial Group LLC grew its stake in shares of Boston Scientific by 29.7% in the first quarter. Leverty Financial Group LLC now owns 3,977 shares of the medical equipment provider’s stock valued at $401,000 after buying an additional 910 shares in the last quarter. Finally, Secure Asset Management LLC acquired a new position in Boston Scientific during the first quarter worth $418,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.